Table 4.
Number of hospitalisations with an associated diagnosis of erythema multiforme (EM) and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) per million sold packages of drug classes involved in adverse reactions; Mainland Portugal, 2010–2014 (n = 215 hospitalisations)
Drug class | EM (N = 90) | SJS/TEN (N = 125) |
---|---|---|
Antibiotics (NPS = 37,311,945) | 0.75 | 0.88 |
Antiviral drugs (NPS = 686,221) | 1.46 | 8.74 |
Hormones and synthetic substitutes (NPS = 69,570,259) | 0.08 | 0.10 |
Antineoplastic and immunosuppressive drugs (NPS = 1,787,045) | 3.92 | 5.60 |
Agents primarily affecting blood constituents (NPS = 37,608,542) | – | 0.11 |
Analgesics, antipyretics, and antirheumatics (NPS = 71,419,516) | 0.12 | 0.10 |
Anticonvulsants (NPS = 16,305,856) | 0.43 | 1.17 |
Psychotropic agents (NPS = 100,008,577) | 0.01 | 0.03 |
Agents primarily affecting the cardiovascular system (NPS = 198,300,264) | 0.01 | 0.01 |
Uric acid metabolism drugs (NPS = 5,007,028) | 2.40 | 4.99 |
NPS number of drug packages sold